Emergent BioSolutions: Top Official Warned That Vaccine Plant Had to Be ‘Monitored Closely`

Mr. de Notaristefani, a former top executive at two major pharmaceutical companies, cited “significant” personnel problems, writing that plans to increase staffing seemed “inadequate to enable the company to manufacture at the required rate.” He also noted that audits by the F.D.A. and individual companies that had hired Emergent “highlighted the need for extensive training…

MHRP launches trial to evaluate IL-15 Agonist as therapy to reduce HIV reservoir

SILVER SPRING, Md. – The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio’s Anktiva® (also called N-803), administered during acute HIV infection as an experimental therapy to target establishment of the HIV…